Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.49 |
| ▸ | RXRB | P28702 | 1/20 | 0.49 |
| ▸ | RXRG | P48443 | 1/20 | 0.49 |
| ▸ | LSS | P48449 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 8/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL346774 | 0.87 | MRGPRX4 (0.48) | RXRARXRBRXRGLSSTACR1 | |
| Hydrochloric Acid SCHEMBL345549 | 0.86 | MRGPRX4 (0.47) | RXRARXRBRXRGLSSTACR1 | |
| SCHEMBL6121602 | 0.86 | MRGPRX4 (0.47) | RXRARXRBRXRGLSSTACR1 | |
| Lithium Ion SCHEMBL6121595 | 0.84 | LSS (0.45) | LSSTACR1CES2SERPINE1ALDH1A1 | |
| SCHEMBL9927096 | 0.83 | TACR1 (0.45) | LSSTACR1CES2SERPINE1 | |
| SCHEMBL21697648 | 0.81 | RXRA (0.52) | RXRARXRBRXRGCES2MAOB | |
| SCHEMBL13099993 | 0.81 | RXRA (0.52) | RXRARXRBRXRGCES2MAOB | |
| SCHEMBL13451382 | 0.80 | TACR1 (0.49) | LSSTACR1SERPINE1ALDH1A1 | |
| SCHEMBL96116 | 0.78 | CES2 (0.67) | RXRARXRBRXRGTACR1CES2 | |
| SCHEMBL16389289 | 0.78 | ALDH1A1 (0.41) | CES2MAOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150087632-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINES DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2015-03-26 | — | — | US | disclosed |
| US-8933085-B2 | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2015-01-13 | — | — | US | disclosed |
| US-20120149681-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149681-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | RXRA 2034/4885RXRB 1654/4885RXRG 2497/4885 |
| US-20150087632-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINES DERIVATIVES AS JAK INHIBITORS | JAK2, JAK1, JAK3 | RXRA 2382/4885RXRB 1988/4885RXRG 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.